All In Biotech

Drug Trial Radar · NCT05658692

Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome

Last checked: Nov 20, 2026Latest source record: Dec 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,000

Planned (sponsor's estimate)

Start

Oct 1, 2022

Primary completion

Oct 2023

Study completion Dec 2023

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Renmin Hospital of Wuhan University; The Second Affiliated Hospital of Harbin Medical University; West China Hospital; The First Affiliated Hospital of Zhengzhou University; Peking Union Medical College Hospital; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Fudan University; Guangdong Provincial People's Hospital; Ningbo No. 1 Hospital; Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
First posted
Dec 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Platform adaptive embedded trial for acute respiratory distress syndrome (PETARDS) is a randomized, embedded, multifactorial, adaptive platform trial for ARDS. The study aimed to assess the impact of multiple interventions on outcomes in patients with ARDS admitted to the ICU.

Conditions

  • Acute Respiratory Distress Syndrome

Interventions

  • protective ventilationDevice

    Patients with moderate to severe ARDS received ventilation treatment according to predicted body weight(PBW) and controlled plateau pressure.

  • prone position ventilationBehavioral

    patients with moderate to severe ARDS who don't have contraindications were given prone ventilation for over 12 hours.

  • glucocorticoid therapyDrug

    Dexamethasone: Patients received intravenous dexamethasone 20 mg daily from days 1 to 5, reduced to 10 mg daily from days 6 to 10. Hydrocortisone:For septic ARDS patients, 50 mg of hydrocortisone was given as an intravenous bolus every 6 hours for 7 days; For patients with COVID-19-related ARDS, The corticosteroid field randomized participants to a fixed 7-day period of intravenous hydrocortisone (50 mg or 100 mg every 6 hours).

  • restrictive fluid resuscitationOther

    1. without other organ dysfunction patients: Minimize fluid was given; 2. other ARDS patients: In the resuscitation phase, controlled fluid replacement combined with vasoactive drugs was given; multiple measures were taken, like lactate and so on, to utilizedto guide fluid resuscitation therapy; diuretics or diuretics in combination with albumin to achieve fluid balance.

  • Thymosin AlphaBiological

    People received thymosin Alpha subcutaneous injections, twice a week.

  • Muscle relaxant therapyDrug

    Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant

  • Integrated Chinese and Western Medicine TreatmentOther

    1. ventilation; 2. conventional western medicine treatment; 3. Chinese herbal medicine(Determining medication based on syndrome differentiation)

  • statin therapyDrug

    1. Simvastatin: 80mg qd po for not more than 28days; 2. Rosuvastatin: 20mg qd po (40mg for the first time) for 28days or 3 days after transfer out of the ICU, or the patient died.

  • anti-infective treatmentCombination product

    According to "Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021".

  • Extracorporeal Membrane Oxygenation(ECMO)Device

    1. For severe ARDS patients with refractory hypoxemia within 7 days of onset; 2. (Inspiratory oxygen concentration) ≥ 0.80, tidal volume 6ml/kg (PBW), positive end-expiratory pressure \[PEEP\] ≥ 10 cmH2O; 3. V-V Model.

  • stem cell therapyGenetic

    A single injection of bone marrow stem cells, doses of 1, 5, 10\*106 cells/kg was taken according to the previous clinical studies.

  • Sedative analgesia/muscle relaxant therapyDrug

    Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant

  • inotropes therapyDrug

    According to "Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021".

  • Vasoactive drug therapyDrug

    According to "Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021".

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ventilator-free daysTime frame: within 28 days

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, China · Recruiting

  • West China Hospital,Sichuan University

    Chengdu, China · Recruiting

  • Guangdong Provincial People's Hospital

    Guangdong, China · Recruiting

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, China · Recruiting

  • Lanxi People's Hospital

    Lanxi, China · Recruiting

  • Ningbo First Hospital

    Ningbo, China · Recruiting

  • Zhognshang hospital, Fudan University

    Shanghai, China · Recruiting

  • Taizhou Hosptial of Zhejiang Province

    Taizhou, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China · Recruiting

  • Wuhan University Renmin Hospital

    Wuhan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.